A phase 1 randomized, blinded, placebo-controlled safety and acceptability study of the UC-781 vaginal microbicide gel formulation applied rectally in HIV-1 seronegative adults
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2016
At a glance
- Drugs UC 781 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 12 May 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 28 Dec 2006 New trial record.